These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21954459)

  • 1. Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients.
    Plaza Z; Soriano V; Gonzalez Mdel M; Di Lello FA; Macias J; Labarga P; Pineda JA; Poveda E
    J Antimicrob Chemother; 2011 Dec; 66(12):2838-42. PubMed ID: 21954459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No influence of antiretroviral therapy on the mutation rate of the HCV NS5B polymerase in HIV/HCV-coinfected patients.
    Di Lello FA; Macias J; Plaza Z; García-Rey S; Soriano V; Cifuentes C; González Mdel M; Parra-Sánchez M; Labarga P; Recio E; Poveda E; Pineda JA
    Antiviral Res; 2012 Aug; 95(2):67-71. PubMed ID: 22683722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients.
    Sede MM; Laufer NL; Quarleri J
    Int J Antimicrob Agents; 2015 Aug; 46(2):219-24. PubMed ID: 26100213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia.
    Aissa Larousse J; Trimoulet P; Recordon-Pinson P; Papuchon J; Azzouz MM; Ben Mami N; Cheikh I; Triki H; Fleury H
    J Med Virol; 2014 Aug; 86(8):1350-9. PubMed ID: 24760718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.
    Le Pogam S; Seshaadri A; Kosaka A; Chiu S; Kang H; Hu S; Rajyaguru S; Symons J; Cammack N; Nájera I
    J Antimicrob Chemother; 2008 Jun; 61(6):1205-16. PubMed ID: 18343801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.
    Alves R; Queiroz AT; Pessoa MG; da Silva EF; Mazo DF; Carrilho FJ; Carvalho-Filho RJ; de Carvalho IM
    J Viral Hepat; 2013 Jun; 20(6):414-21. PubMed ID: 23647958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients.
    Winters MA; Chary A; Eison R; Asmuth D; Holodniy M
    J Med Virol; 2010 May; 82(5):791-8. PubMed ID: 20336744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.
    Costantino A; Spada E; Equestre M; Bruni R; Tritarelli E; Coppola N; Sagnelli C; Sagnelli E; Ciccaglione AR
    Virol J; 2015 Nov; 12():186. PubMed ID: 26577836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
    Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
    Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diversity of the hepatitis C virus NS5B gene during HIV co-infection.
    Ngwaga T; Kong L; Lin D; Schoborg C; Taylor LE; Mayer KH; Klein RS; Celentano DD; Sobel JD; Jamieson DJ; King CC; Tavis JE; Blackard JT
    PLoS One; 2020; 15(8):e0237162. PubMed ID: 32750098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
    Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G
    PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.
    Di Maio VC; Cento V; Mirabelli C; Artese A; Costa G; Alcaro S; Perno CF; Ceccherini-Silberstein F
    Antimicrob Agents Chemother; 2014 May; 58(5):2781-97. PubMed ID: 24590484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple Introduction and Naturally Occuring Drug Resistance of HCV among HIV-Infected Intravenous Drug Users in Yunnan: An Origin of China's HIV/HCV Epidemics.
    Chen M; Ma Y; Chen H; Luo H; Dai J; Song L; Yang C; Mei J; Yang L; Dong L; Jia M; Lu L
    PLoS One; 2015; 10(11):e0142543. PubMed ID: 26562015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
    Costa VD; Brandão-Mello CE; Nunes EP; Dos Santos Silva PGC; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
    PLoS One; 2019; 14(5):e0216327. PubMed ID: 31063475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients.
    Treviño A; de Mendoza C; Parra P; Rodríguez C; Madejón A; Plaza Z; del Romero J; Poveda E; Soriano V
    Antivir Ther; 2011; 16(3):413-6. PubMed ID: 21555824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV.
    Noble CF; Malta F; Lisboa-Neto G; Gomes-Gouvêa MS; Leite AGB; de Castro VFD; Santana RAF; Carrilho FJ; Mendes-Correa MC; Pinho JRR
    Arch Virol; 2017 Jan; 162(1):165-169. PubMed ID: 27704215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria.
    Shenge JA; Odaibo GN; Olaleye DO
    PLoS One; 2019; 14(2):e0210724. PubMed ID: 30726229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.
    Gaudieri S; Rauch A; Pfafferott K; Barnes E; Cheng W; McCaughan G; Shackel N; Jeffrey GP; Mollison L; Baker R; Furrer H; Günthard HF; Freitas E; Humphreys I; Klenerman P; Mallal S; James I; Roberts S; Nolan D; Lucas M
    Hepatology; 2009 Apr; 49(4):1069-82. PubMed ID: 19263475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China.
    Zhou K; Liang Z; Wang C; Hu F; Ning C; Lan Y; Tang X; Tucker JD; Cai W
    PLoS One; 2016; 11(6):e0157438. PubMed ID: 27341031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Naturally occurring NS5B variants resistant to non-nucleoside or nucleoside polymerase inhibitors among treatment-naïve hepatitis C patients in south China].
    Li Z; Liu Y; Cai Q; Shao X; Yan Y; Zhao Z
    Zhonghua Gan Zang Bing Za Zhi; 2015 Sep; 23(9):653-7. PubMed ID: 26524357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.